AtriCure Upgraded to “Outperform” at JMP Securities (ATRC)
AtriCure (NASDAQ:ATRC) was upgraded by JMP Securities from a “market perform” rating to an “outperform” rating in a research note issued on Friday, TheFlyOnTheWall.com reports.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of AtriCure from $19.00 to $25.00 in a research note to investors on Friday.
Shares of AtriCure (NASDAQ:ATRC) traded up 17.52% on Friday, hitting $22.34. The stock had a trading volume of 696,608 shares. AtriCure has a one year low of $7.39 and a one year high of $19.20. The stock’s 50-day moving average is $16.84 and its 200-day moving average is $12.36. The company’s market cap is $469.6 million.
AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. The company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $18.30 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 24.8% on a year-over-year basis. On average, analysts predict that AtriCure will post $-0.46 earnings per share for the current fiscal year.
AtriCure, Inc, is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.